+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lanreotide"

From
From
Somatostatin Analogs - Global Strategic Business Report - Product Thumbnail Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • April 2025
  • 94 Pages
  • Global
From
Acromegaly Market Report 2025 - Product Thumbnail Image

Acromegaly Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Somatostatin Analogs Market Report 2025 - Product Thumbnail Image

Somatostatin Analogs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
Acromegaly - Pipeline Insight, 2024 - Product Thumbnail Image

Acromegaly - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
From
Acromegaly - Pipeline Review, H2 2020 - Product Thumbnail Image

Acromegaly - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 96 Pages
  • Global
From
From
From
  • 18 Results (Page 1 of 1)
Loading Indicator

Lanreotide is a medication used to treat endocrine and metabolic disorders. It is a somatostatin analogue, which works by blocking the release of hormones from the pituitary gland. It is used to treat acromegaly, a condition caused by an overproduction of growth hormone, and neuroendocrine tumors, which are tumors that originate in the endocrine system. It is also used to treat carcinoid syndrome, a condition caused by the overproduction of serotonin. Lanreotide is available in both injectable and capsule forms. The injectable form is administered subcutaneously, while the capsule form is taken orally. The medication is typically taken once or twice a day, depending on the condition being treated. The lanreotide market is a growing one, with many companies offering the medication. Some of these companies include Novartis, Ipsen, and Teva Pharmaceuticals. Show Less Read more